Literature DB >> 16049057

Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats.

Matthew J Huentelman1, Justin L Grobe, Jorge Vazquez, Jillian M Stewart, Adam P Mecca, Michael J Katovich, Carlos M Ferrario, Mohan K Raizada.   

Abstract

Angiotensin converting enzyme 2 (ACE2), a newly discovered member of the renin-angiotensin system (RAS), is a potential therapeutic target for the control of cardiovascular disease owing to its key role in the formation of vasoprotective peptides from angiotensin II. The aim of the present study was to evaluate whether overexpression of ACE2 could protect the heart from angiotensin II-induced hypertrophy and fibrosis. Lentiviral vector encoding mouse ACE2 (lenti-mACE2) or GFP was injected intracardially in 5-day-old Sprague-Dawley rats. This resulted in expression of mACE2 in cardiac tissue for the duration of the study. Infusion of 200 ng kg-1 min-1 angiotensin II for 4 weeks resulted in an 80 mmHg increase in systolic blood pressure, a significant increase in the heart weight to body weight ratio (HW:BW), and marked myocardial fibrosis in control rats. Transduction with lenti-mACE2 resulted in significant attenuation of the increased HW:BW and myocardial fibrosis induced by angiotensin II infusion. These observations demonstrate that ACE2 overexpression results in protective effects on angiotensin II-induced cardiac hypertrophy and fibrosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16049057     DOI: 10.1113/expphysiol.2005.031096

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  94 in total

Review 1.  Role of ACE2 in diastolic and systolic heart failure.

Authors:  Wang Wang; Sreedhar Bodiga; Subhash K Das; Jennifer Lo; Vaibhav Patel; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

2.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

3.  ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension.

Authors:  Srinivas Sriramula; Jeffrey P Cardinale; Eric Lazartigues; Joseph Francis
Journal:  Cardiovasc Res       Date:  2011-09-27       Impact factor: 10.787

4.  Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2.

Authors:  Minghao Ye; Jan Wysocki; Francisco R Gonzalez-Pacheco; Mahmoud Salem; Karla Evora; Laura Garcia-Halpin; Marko Poglitsch; Manfred Schuster; Daniel Batlle
Journal:  Hypertension       Date:  2012-07-09       Impact factor: 10.190

Review 5.  Angiotensin-converting enzymes and drug discovery in cardiovascular diseases.

Authors:  Lijun Shi; Caiping Mao; Zhice Xu; Lubo Zhang
Journal:  Drug Discov Today       Date:  2010-02-17       Impact factor: 7.851

Review 6.  Angiotensin-(1-7) as an antihypertensive, antifibrotic target.

Authors:  Michael J Katovich; Justin L Grobe; Mohan K Raizada
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

7.  Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays.

Authors:  Kim Brint Pedersen; Srinivas Sriramula; Kavaljit H Chhabra; Huijing Xia; Eric Lazartigues
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-31       Impact factor: 3.619

8.  Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer.

Authors:  Yoriko Yamazato; Anderson J Ferreira; Kwon-Ho Hong; Srinivas Sriramula; Joseph Francis; Masanobu Yamazato; Lihui Yuan; Chastity N Bradford; Vinayak Shenoy; Suk P Oh; Michael J Katovich; Mohan K Raizada
Journal:  Hypertension       Date:  2009-06-29       Impact factor: 10.190

Review 9.  New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism.

Authors:  Carlos M Ferrario
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

Review 10.  The sweeter side of ACE2: physiological evidence for a role in diabetes.

Authors:  Sharell M Bindom; Eric Lazartigues
Journal:  Mol Cell Endocrinol       Date:  2008-10-01       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.